[Pulchinenoside control MeCP2 expression in FLS from RA model rats].

Area of Science:

• Rheumatology
• Molecular Biology
• Pharmacology

Context:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction.
• Fibroblast-like synoviocytes (FLS) play a crucial role in RA pathogenesis by promoting synovial hyperplasia and joint damage.
• Methyl CpG binding protein 2 (MeCP2) is implicated in regulating gene expression relevant to inflammatory diseases.

Purpose:

• To investigate the therapeutic potential of pulchinenoside (PULC) in a rat model of rheumatoid arthritis (RA).
• To elucidate the molecular mechanisms underlying PULC's effects on MeCP2 expression, SFRP2, β-catenin, and FLS proliferation in RA.
• To assess the impact of PULC on the Wnt signaling pathway in RA-affected FLS.

Summary:

• Adjuvant arthritis rats were used to model RA, and their fibroblast-like synoviocytes (FLS) were treated with PULC or MeCP2 siRNA.
• PULC treatment down-regulated MeCP2 expression, up-regulated SFRP2 expression, and inhibited FLS proliferation.
• MeCP2 siRNA mimicked PULC's effects, confirming MeCP2 inhibition as a key mechanism, and also inhibited β-catenin expression.

Impact:

• Pulchinenoside (PULC) demonstrates potential as a novel therapeutic agent for rheumatoid arthritis (RA).
• PULC may exert its anti-RA effects by inhibiting MeCP2 expression, subsequently suppressing the Wnt signaling pathway.
• This mechanism leads to reduced FLS proliferation, offering a new target for RA treatment development.